Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05987553
Other study ID # 2020-1334
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 1, 2024

Study information

Verified date April 2024
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The evaluation on the diagnostic accuracy of actinic keratosis recognition by general practitioners before and after participation on an e-learning program.


Description:

Actinic keratosis is defined as the most frequent common intra-epithelial neoplasm in the Caucasian population, with an increasing prevalence. If left untreated, actinic keratosis has the potency to develop into a cutaneous squamous-cell carcinoma. Treatment of actinic keratosis is aimed at both lesion reduction and to prevent malignant transformation. To achieve treatment adherence for patients, it is necessary to raise physician awareness about actinic keratosis. This study primarily aimed to investigate whether the sensitivity of establishing a correct actinic keratosis diagnosis by general practitioners (in training) would increase after participating in an e-learning program about the recognition of actinic keratosis. This was achieved by comparing the results of a pre- and post-test completed by general practitioners which was incorporated in the e-learning program.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date December 1, 2024
Est. primary completion date January 1, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria: - general practitioner in the Netherlands - access to e-learning module via phone/computer/tablet - knowledge of the Dutch language Exclusion Criteria: - no knowledge of the Dutch language - different specialists than general practitioner

Study Design


Related Conditions & MeSH terms


Intervention

Other:
e-learning program
All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.

Locations

Country Name City State
Netherlands Ellen Oyen Maastricht

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in sensitivity Difference in sensitivity of participants in the recognition of actinic keratosis, before and after the use of an e-learning program (paired). Measurement by baseline and after finalising the e-learning program (same day up until 30 days)
Primary Difference in specificity Difference in specificity of participants in the recognition of actinic keratosis, before and after the use of an e-learning program (paired). Measurement by baseline and after finalising the e-learning program (same day up until 30 days)
Secondary Difference in area under the receiver operating characteristic (ROC) curve Difference in area under the curve of participants in the recognition of actinic keratosis, before and after the use of an e-learning program. Measurement by baseline and after finalising the e-learning program (same day up until 30 days)
See also
  Status Clinical Trial Phase
Completed NCT03575780 - Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis Phase 1
Completed NCT04085367 - Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face Phase 3
Completed NCT05937529 - Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis N/A
Completed NCT02520700 - A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses N/A
Terminated NCT01538901 - Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Phase 4
Completed NCT01354717 - Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo Phase 3
Completed NCT00742391 - A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Phase 3
Completed NCT03285477 - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp Phase 3
Suspended NCT03963102 - Duration of Ameluz Application in Acral Actinic Keratoses Response Phase 4
Not yet recruiting NCT05923060 - Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses Phase 2
Withdrawn NCT06026358 - Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands Phase 4
Completed NCT02622594 - Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Phase 4
Completed NCT00786994 - The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses Phase 2
Completed NCT00774787 - Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Phase 4
Completed NCT00544258 - Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005 Phase 1
Completed NCT04024579 - Treatment of Actinic Keratosis With 5% KOH Solution
Completed NCT04843553 - Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients Early Phase 1
Completed NCT03315286 - Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure N/A
Completed NCT03279328 - Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Phase 4
Completed NCT02062853 - Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video N/A